ABSTRACT
BACKGROUND: We hypothesized that the induction of monocyte activation biomarkers, especially soluble urokinase-type plasminogen activator receptor (suPAR) and interferon γ-inducible protein 10 (IP-10), is lower in HIV-1C than HIV-1B, owing to a defective Tat cysteine dimotif (C30S). METHODS: A total of 68 paired cerebrospinal fluid (CSF) and blood samples from people with HIV (PWH), free of CNS opportunistic infections, from a Southern Brazil outpatient HIV clinic were evaluated such as HIV-1B subtype (n = 27), HIV-1C (n = 26), other (n = 15), and 19 HIV-negative controls. The levels of suPAR, IP-10, neopterin, and ß2 microglobulin (ß2m) in the CSF and serum were quantified using different immunoassays. RESULTS: Overall, in PWH, increases in CSF suPAR, CSF/serum suPAR, and CSF/serum ß2m correlated with worse working memory deficits (r = 0.303, 0.353, and 0.289, respectively, all P < 0.05). The medians of IP-10, suPAR, neopterin, and ß2m in CSF and serum and the CSF/serum ratio and suPAR index were comparable between the HIV-1B and HIV-1C subtypes. CSF IP-10 and neopterin and serum IP-10 and suPAR levels were higher in PWH than the HIV-negative controls (P = 0.015, P = 0.001, P < 0.0001, and P < 0.001, respectively). The serum ß2m level was higher in HIV-associated dementia than neuropsychologically normal or asymptomatic (P = 0.024). DISCUSSION: We observed that higher levels of CSF suPAR and the suPAR quotient correlated with worse working memory deficit. Elevated levels of monocyte activation were similar in both HIV-1 B and C subtypes, providing no evidence of reduced neuropathogenicity of HIV-1 subtype C Tat compared with subtype B.
Subject(s)
AIDS Dementia Complex , Chemokine CXCL10 , HIV Infections , Memory Disorders , Receptors, Urokinase Plasminogen Activator , AIDS Dementia Complex/cerebrospinal fluid , AIDS Dementia Complex/virology , Biomarkers/cerebrospinal fluid , Case-Control Studies , Chemokine CXCL10/cerebrospinal fluid , HIV Infections/cerebrospinal fluid , HIV Infections/virology , HIV-1 , Humans , Memory Disorders/cerebrospinal fluid , Memory Disorders/virology , Neopterin , Receptors, Urokinase Plasminogen Activator/metabolismABSTRACT
OBJECTIVE: To determine whether memory tasks with demonstrated sensitivity to hippocampal function can detect variance related to preclinical Alzheimer disease (AD) biomarkers, we examined associations between performance in 3 memory tasks and CSF ß-amyloid (Aß)42/Aß40 and phosopho-tau181 (p-tau181) in cognitively unimpaired older adults (CU). METHODS: CU enrolled in the Stanford Aging and Memory Study (n = 153; age 68.78 ± 5.81 years; 94 female) completed a lumbar puncture and memory assessments. CSF Aß42, Aß40, and p-tau181 were measured with the automated Lumipulse G system in a single-batch analysis. Episodic memory was assayed using a standardized delayed recall composite, paired associate (word-picture) cued recall, and a mnemonic discrimination task that involves discrimination between studied "target" objects, novel "foil" objects, and perceptually similar "lure" objects. Analyses examined cross-sectional relationships among memory performance, age, and CSF measures, controlling for sex and education. RESULTS: Age and lower Aß42/Aß40 were independently associated with elevated p-tau181. Age, Aß42/Aß40, and p-tau181 were each associated with (1) poorer associative memory and (2) diminished improvement in mnemonic discrimination performance across levels of decreased task difficulty (i.e., target-lure similarity). P-tau mediated the effect of Aß42/Aß40 on memory. Relationships between CSF proteins and delayed recall were similar but nonsignificant. CSF Aß42 was not significantly associated with p-tau181 or memory. CONCLUSIONS: Tests designed to tax hippocampal function are sensitive to subtle individual differences in memory among CU and correlate with early AD-associated biomarker changes in CSF. These tests may offer utility for identifying CU with preclinical AD pathology.
Subject(s)
Alzheimer Disease/cerebrospinal fluid , Biomarkers/cerebrospinal fluid , Hippocampus/physiopathology , Memory Disorders/cerebrospinal fluid , Memory Disorders/psychology , Aged , Aged, 80 and over , Aging/psychology , Alzheimer Disease/physiopathology , Alzheimer Disease/psychology , Amyloid beta-Peptides/cerebrospinal fluid , Association Learning , Cross-Sectional Studies , Cues , Discrimination, Psychological , Female , Humans , Male , Memory , Memory Disorders/physiopathology , Memory, Episodic , Mental Recall , Middle Aged , Neuropsychological Tests , Peptide Fragments/cerebrospinal fluid , Psychomotor Performance , tau Proteins/cerebrospinal fluidABSTRACT
BACKGROUND: Alzheimer's disease (AD) is frequently accompanied by sleep impairment, which can induce AD-related neurodegeneration. We herein investigated the sleep architecture, cognition, and cerebrospinal fluid (CSF) biomarkers (tau proteins and ß-amyloid42) during AD progression from subjective cognitive impairment (SCI) to mild cognitive impairment (MCI) and eventually to AD dementia, and compared the results with cognitively normal (CN) subjects. METHODS: We included patients affected by SCI, MCI, mild AD, and moderate-to-severe AD in our study along with CN subjects as controls. All the subjects underwent nocturnal polysomnography to investigate sleep, neuropsychological testing to evaluate cognition, and lumbar puncture for CSF AD biomarkers assessment. RESULTS: Sleep (both rapid eye movement (REM) and non-REM sleep) and memory function are both progressively impaired during the course of AD from SCI to mild and subsequently to moderate AD. Further, sleep dysregulation appears earlier than cognitive deterioration, with a reduction of CSF ß-amyloid42 level. CONCLUSION: Sleep, memory, and CSF AD biomarkers are closely interrelated in AD progression from the earliest asymptomatic and preclinical stages of the disease related in AD since the earliest and preclinical stages of the disease.
Subject(s)
Alzheimer Disease/complications , Biomarkers/cerebrospinal fluid , Cognitive Dysfunction/etiology , Memory Disorders/etiology , Sleep Wake Disorders/etiology , Adult , Aged , Aged, 80 and over , Alzheimer Disease/cerebrospinal fluid , Amyloid beta-Peptides/cerebrospinal fluid , Cognitive Dysfunction/cerebrospinal fluid , Disease Progression , Female , Humans , Male , Memory Disorders/cerebrospinal fluid , Middle Aged , Sleep Wake Disorders/cerebrospinal fluid , tau Proteins/cerebrospinal fluidABSTRACT
Our aim is to compare olfactory and gustatory function and food preferences of patients with Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD) with controls. We included 22 patients with MCI, 30 patients with AD and 40 controls and assessed olfactory threshold, odor discrimination and odor identification (Sniffin' Sticks), gustatory functioning (Taste Strips), and food preferences (Macronutrient and Taste Preference Ranking Task). Linear regression analyses were used to study associations of five cognitive domains or AD biomarkers with olfactory functioning. Groups did not differ in olfactory threshold, gustatory function and food preferences. Patients with MCI and AD scored lower on odor discrimination and identification than controls. Poorer memory, but no other cognitive domain, was associated with poorer odor discrimination and odor identification, but not with odor threshold. No associations with AD biomarkers were found. In conclusion, patients with MCI and AD have poorer odor discrimination and identification ability than controls, but similar detection thresholds. This is likely a consequence of poorer memory rather than directly caused by AD pathology.
Subject(s)
Alzheimer Disease/physiopathology , Cognitive Dysfunction/physiopathology , Discrimination, Psychological/physiology , Memory Disorders/physiopathology , Olfaction Disorders/physiopathology , Taste Perception/physiology , Aged , Aged, 80 and over , Alzheimer Disease/cerebrospinal fluid , Alzheimer Disease/complications , Cognitive Dysfunction/cerebrospinal fluid , Cognitive Dysfunction/complications , Cohort Studies , Female , Food Preferences , Humans , Male , Memory Disorders/cerebrospinal fluid , Memory Disorders/complications , Middle Aged , Olfaction Disorders/etiologyABSTRACT
OBJECTIVE: To examine whether the use of sex-specific norms and cut scores to identify memory impairment improves diagnostic accuracy of amnestic mild cognitive impairment (aMCI) compared to non-sex-specific (typical) norms/cut scores given the female advantage in verbal memory. METHODS: We calculated sex-specific and typical norms/cut scores (age and education specific) for impairment on the Rey Auditory Verbal Learning Test in the Mayo Clinic Study of Aging. Norms/cut scores were applied to 453 women and 532 men from the Alzheimer's Disease Neuroimaging Initiative. We compared sex differences in rates of aMCI (Jak/Bondi criteria) for sex-specific vs typical norms/cut scores. Using sex-specific cut scores as the true condition and typical cut scores as the predicted condition, we categorized participants as true positives (TPs), false positives (FPs), true negative (TNs), or false negative (FNs). In cross-sectional analyses within sex, we compared positivity rates of CSF hyperphosphorylated tau/ß-amyloid (Aß) and cortical Aß deposition ([18F]AV45 PET) and APOE ε4 frequency among diagnostic comparison groups. RESULTS: The frequency of aMCI was higher in men when using typical norms/cut scores. Using sex-adjusted norms/cut scores led to the identification of 10% FNs (missed aMCI cases) among women and 10% FPs among men. Biomarker analyses supported the hypothesis that sex-specific diagnostic criteria improves diagnostic accuracy. Biomarkers rates were higher in FNs vs TNs and similar in FNs and TPs. Biomarker rates were lower in FPs vs TPs and similar between FPs and TNs. CONCLUSION: Results suggest that non-sex-specific aMCI diagnostic criteria led to a 20% diagnostic error rate. Accounting for sex differences in verbal memory performance may improve aMCI classification.
Subject(s)
Cognitive Dysfunction/diagnosis , Memory Disorders/diagnosis , Memory and Learning Tests , Aged , Aged, 80 and over , Amyloid beta-Peptides/cerebrospinal fluid , Amyloid beta-Peptides/metabolism , Apolipoprotein E4/genetics , Cerebral Cortex/diagnostic imaging , Cognitive Dysfunction/cerebrospinal fluid , Cognitive Dysfunction/diagnostic imaging , Cognitive Dysfunction/psychology , Humans , Memory Disorders/cerebrospinal fluid , Memory Disorders/diagnostic imaging , Memory Disorders/psychology , Mental Status and Dementia Tests , Positron-Emission Tomography , Reference Values , Sex Factors , tau Proteins/cerebrospinal fluidABSTRACT
The independent effects of different brain pathologies on age-dependent cognitive decline are unclear. We examined this in 300 cognitively unimpaired elderly individuals from the BioFINDER study. Using cognition as outcome we studied the effects of cerebrospinal fluid biomarkers for amyloid-ß (Aß42/40), neuroinflammation (YKL-40), and neurodegeneration and tau pathology (T-tau and P-tau) as well as MRI measures of white-matter lesions, hippocampal volume (HV), and regional cortical thickness. We found that Aß positivity and HV were independently associated with memory. Results differed depending on age, with memory being associated with HV (but not Aß) in older participants (73.3-88.4 years), and with Aß (but not HV) in relatively younger participants (65.2-73.2 years). This indicates that Aß and atrophy are independent contributors to memory variability in cognitively healthy elderly and that Aß mainly affects memory in younger elderly individuals. With advancing age, the effect of brain atrophy overshadows the effect of Aß on memory function.
Subject(s)
Amyloid beta-Peptides/cerebrospinal fluid , Cognition/physiology , Hippocampus/pathology , Memory Disorders/physiopathology , Memory/physiology , Peptide Fragments/cerebrospinal fluid , Age Factors , Aged , Aged, 80 and over , Aging/physiology , Atrophy/cerebrospinal fluid , Atrophy/diagnosis , Biomarkers/cerebrospinal fluid , Cerebral Cortex/diagnostic imaging , Cerebral Cortex/physiopathology , Chitinase-3-Like Protein 1/cerebrospinal fluid , Cohort Studies , Cross-Sectional Studies , Female , Healthy Volunteers , Hippocampus/diagnostic imaging , Humans , Magnetic Resonance Imaging , Male , Memory Disorders/cerebrospinal fluid , Memory Disorders/diagnosis , Memory Disorders/pathology , tau Proteins/cerebrospinal fluidABSTRACT
BACKGROUND: The use of biomarkers, in particular amyloid-ß (Aß) changes, has allowed the possibility to identify patients with subjective memory complaints (SMCs) and amnestic mild cognitive impairment (aMCI) who suffer from Alzheimer's disease (AD). Since it is unfeasible that all patients with aMCI could presently undergo biomarkers assessment, it would be important that SMCs might contribute to identify the aMCI patients who have AD amyloid pathology. OBJECTIVES: To know whether aMCI patients with amyloid biomarkers (Aß+) present greater SMCs as compared to those without amyloid biomarkers (Aß-). METHODS: Participants were selected from a cohort of nondemented patients with cognitive complaints and a comprehensive neuropsychological evaluation, on the basis of 1) diagnosis of aMCI; 2) detailed assessment of memory difficulties with the SMC Scale; and 3) known amyloid status. The amyloid status was determined on the basis of either CSF Aß1-42 concentration or amyloid PET imaging. RESULTS: Of the 176 patients with aMCI studied, 90 were Aß+ and 86 were Aß-. The two groups did not differ in terms of age, gender, and education. The SMC total score was not significantly different in the Aß+ aMCI patients (9.48±4.18) when compared to the Aß- aMCI patients (10.52±4.57). The Aß+ aMCI patients had lower scores on the MMSE and memory/learning tests, but not on the Geriatric Depression Scale, when comparing to the Aß- aMCI patients. CONCLUSIONS: Evaluating SMCs does not seem helpful to identify, among patients with aMCI, those who have AD.
Subject(s)
Amyloid beta-Peptides/cerebrospinal fluid , Cognitive Dysfunction/cerebrospinal fluid , Cognitive Dysfunction/diagnosis , Diagnostic Self Evaluation , Memory Disorders/cerebrospinal fluid , Memory Disorders/diagnosis , Peptide Fragments/cerebrospinal fluid , Aged , Amnesia/cerebrospinal fluid , Amnesia/diagnosis , Amnesia/psychology , Cognitive Dysfunction/psychology , Cohort Studies , Female , Humans , Male , Memory Disorders/psychology , Mental Status and Dementia Tests , Middle AgedABSTRACT
BACKGROUND: We investigated a sample of cognitively healthy subjects with normal Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarker levels to identify the earliest variables related to longitudinal memory changes. OBJECTIVE: Employing a new highly demanding learning and memory test (the Ancient Farming Equipment Test; AFE-T), we aimed to investigate whether a biomarker related to neurodegeneration (i.e., CSF tau) was associated with longitudinal memory decline. METHODS: Thirty-two cognitively and biologically normal (CBN) subjects underwent MRI, neuropsychological assessment, and the AFE-T at baseline and 18 months later. To explore the relationship between cognitive performance and relevant factors, a linear model was set up. For a secondary analysis that further explore the effect of tau, the subjects were divided into CBN-Tau↓ (tauâ<â228.64âpg/ml; nâ=â16) and CBN-Tau↑ (tauâ>â228.64âpg/ml; nâ=â16). We also performed voxel-based morphometry (VBM) to identify regions of grey matter volume that would predict both baseline and longitudinal cognitive performance. RESULTS: Our main finding was an association between CSF tau and longitudinal memory decline measured with AFE-T (Bâ=â-0.17, pâ<â0.05; râ=â-0.414; pâ<â0.01), and further analyses showed different evolvement between subgroups, with an accelerated decline in individuals with higher tau (F(1,31)â=â8.37; pâ<â0.01). VBM results suggested that AFE-T performance is related to grey matter volume in a medial temporal, middle frontal, and posterior cerebellar network at baseline, and that there are strategic brain areas driving the longitudinal cognitive changes. CONCLUSIONS: The present findings provide evidence for structural and biological markers linked to cognitive aging by highlighting the role of tau, a marker of neurodegeneration, which can be related with the earliest memory changes in healthy subjects.
Subject(s)
Alzheimer Disease/cerebrospinal fluid , Cognition/physiology , Cognitive Dysfunction/cerebrospinal fluid , Memory Disorders/cerebrospinal fluid , tau Proteins/cerebrospinal fluid , Aged , Alzheimer Disease/diagnostic imaging , Biomarkers/cerebrospinal fluid , Brain/diagnostic imaging , Cognitive Dysfunction/diagnostic imaging , Female , Healthy Volunteers , Humans , Magnetic Resonance Imaging , Male , Memory Disorders/diagnostic imaging , Middle Aged , Neuropsychological Tests , PhosphorylationABSTRACT
OBJECTIVE: To investigate the relationship between cerebrospinal fluid (CSF) ß-amyloid peptide (Aß42) and CSF Tau in a large population of patients referred to memory clinics for investigation of cognitive dysfunction. METHODS: We analyzed Alzheimer's disease (AD) biomarkers in CSF taken from 3565 patients referred to 18 French memory clinics. Patients were classified into four profiles according to levels of CSF biomarkers (A: amyloidosis, N: neurodegeneration). The association between CSF Tau and CSF Aß42 were analyzed using general linear regression models, in the overall population and stratified by biomarkers profiles. We compared linear and quadratic models using Akaike information criterion. We also assessed change in biomarker profiles in a subset of patients who had 2 assessments of biomarkers. RESULTS: CSF Tau was negatively associated with CSF Aß42 in the overall population, following a non-linear quadratic model. However, the nature of this association was different in the 4 profiles: positive association in A-N- profile, negative association in A-N+ and A+N+ profiles, lack of association in A+N- patients. When considering patients with longitudinal data on profiles, 36% of those initially classified as A-N+ evolved to an A+N+ profile. CONCLUSIONS: The nature of the association between CSF Aß42 and CFS Tau depends on the A/N profiles of patients. These results suggest an increase in CSF Aß42 early in the disease before its decline while tau pathology progresses, this pattern is particularly observed in non-APOE4 subjects. This phenomenon may explain why some patients with neurodegeneration only markers convert to an AD profile (A+N+) over time.
Subject(s)
Alzheimer Disease/cerebrospinal fluid , Amyloid beta-Peptides/cerebrospinal fluid , tau Proteins/cerebrospinal fluid , Aged , Aged, 80 and over , Amyloidosis/cerebrospinal fluid , Apolipoproteins E/genetics , Biomarkers , Cognition Disorders/cerebrospinal fluid , Cognitive Dysfunction/cerebrospinal fluid , Disease Progression , Female , France , Humans , Longitudinal Studies , Male , Memory Disorders/cerebrospinal fluid , Middle Aged , Neurodegenerative Diseases/cerebrospinal fluid , Peptide Fragments/cerebrospinal fluid , Regression Analysis , Spinal PunctureABSTRACT
With increasing prevalence of Alzheimer's disease (AD) and advances in research of therapeutic approaches, an early and accurate in-vivo diagnosis is crucial. Different biomarkers that are able to identify AD are currently in focus. However, whether and to which extend results of cerebrospinal fluid (CSF) and imaging biomarkers are comparable, is unclear. This study aims to correlate CSF and amyloid imaging biomarkers comparing them to cognitive measurements in order to determine whether these methods provide identical or complementary information. The study comprises 33 consecutive patients with suspected cognitive decline that underwent lumbar puncture for CSF biomarker analysis and Amyloid-PET/CT within the diagnostic evaluation of memory impairment. Amyloid PET/CTs were evaluated visually and quantitatively. CSF and imaging data were retrospectively evaluated and results were compared to cognition tests, age, gender, and ApoE status. Global cortex SUVr levels correlated highly with CSF Aß42/40 and moderately with Aß42 but not with Aß40. Global cortex SUVr and Aß42/40 correlated with mini mental status examination. This study indicates that Amyloid-PET and CSF biomarkers might not reflect identical clinical information and a combination of both seems to be the most accurate way to characterize clinically unclear cognitive decline.
Subject(s)
Amyloid beta-Peptides/cerebrospinal fluid , Memory Disorders/cerebrospinal fluid , Memory Disorders/diagnostic imaging , Positron Emission Tomography Computed Tomography , Aged , Aging/metabolism , Apolipoproteins E/cerebrospinal fluid , Biomarkers/cerebrospinal fluid , Case-Control Studies , Cognition , Cohort Studies , Female , Humans , Male , Memory Disorders/physiopathology , Middle Aged , Retrospective Studies , Sex CharacteristicsABSTRACT
OBJECTIVES: The present study investigated the independent and synergistic effects of amyloid beta (Aß1-42) and phosphorylated tau (Ptau) pathologies on neuropsychological profiles and trajectories in cognitively normal older adults. METHODS: Alzheimer's Disease Neuroimaging Initiative participants identified as cognitively normal at baseline underwent longitudinal assessment (N=518; 0, 12, 24, 36 months), baseline lumbar puncture and follow-up cognitive exams. Cerebral spinal fluid (CSF) biomarker profiles (Aß-Ptau-, Aß+Ptau-, Aß-Ptau+, Aß+Ptau+) were compared on baseline profiles and trajectories for memory (Rey Auditory Verbal Learning Test), attention/executive function (Trail Making Test, A and B), language (Animal Fluency, Vegetable Fluency, Boston Naming Test) and processing speed (Digit Symbol) using multilevel models. RESULTS: The Aß+Ptau+ group exhibited significantly worse baseline performance on tests of memory and executive function relative to the Aß-Ptau+ and Aß-Ptau- groups. The Aß+Ptau- group fell between the Aß+Ptau+ participants and the Aß-Ptau- and Aß-Ptau+ groups on all three cognitive domains and exhibited worse baseline executive function. The Aß-Ptau+ group performed worse than Aß-Ptau- participants on processing speed. Over 36-month follow-up, the Aß+Ptau+ group exhibited the greatest declines in memory and semantic fluency compared to all other groups. CONCLUSIONS: Cognitively normal older adults with both Aß and Ptau pathology exhibited the weakest profile, marked by the worst memory decline compared to the other groups. Other subtle changes in this group included declines in executive function and semantic fluency. Those with Ptau pathology alone showed slowed processing speed, and those with Aß pathology alone showed worse attention and executive function compared to biomarker negative participants. (JINS, 2018, 24, 693-702).
Subject(s)
Alzheimer Disease/cerebrospinal fluid , Alzheimer Disease/physiopathology , Attention/physiology , Executive Function/physiology , Memory Disorders/cerebrospinal fluid , Memory Disorders/physiopathology , Prodromal Symptoms , Aged , Aged, 80 and over , Alzheimer Disease/complications , Amyloid beta-Peptides/cerebrospinal fluid , Cross-Sectional Studies , Databases, Factual , Female , Humans , Longitudinal Studies , Male , Memory Disorders/etiology , tau Proteins/cerebrospinal fluidABSTRACT
There is mounting evidence that prospective memory (PM) is impaired during HIV infection despite treatment. In this prospective study, 66 adults (43 HIV+ and 23 HIV negative) underwent PM assessment and cerebrospinal fluid (CSF) examination. HIV+ participants had significantly lower PM but significantly higher CSF concentrations of CXCL10 and quinolinic acid (QUIN). Higher CSF phosphorylated Tau (pTau) was associated with worse PM. In a secondary analysis excluding outliers, higher QUIN correlated with higher pTau. CSF QUIN is thus elevated during HIV infection despite antiretroviral therapy and could indirectly contribute to impaired PM by influencing the formation of pTau.
Subject(s)
AIDS Dementia Complex/cerebrospinal fluid , Biomarkers/cerebrospinal fluid , Memory Disorders/cerebrospinal fluid , Quinolinic Acid/cerebrospinal fluid , tau Proteins/cerebrospinal fluid , AIDS Dementia Complex/complications , Adult , Female , Humans , Male , Memory Disorders/etiology , Memory, Episodic , Middle Aged , PhosphorylationABSTRACT
BACKGROUND: Diffusion imaging has demonstrated sensitivity to structural brain changes in Alzheimer's disease (AD). However, there remains a need for a more complete characterization of microstructural alterations occurring at the earliest disease stages, and how these changes relate to underlying neuropathology. This study evaluated the sensitivity of restriction spectrum imaging (RSI), an advanced diffusion magnetic resonance imaging (MRI) technique, to microstructural brain changes in mild cognitive impairment (MCI) and AD. METHODS: MRI and neuropsychological test data were acquired from 31 healthy controls, 12 individuals with MCI, and 13 individuals with mild AD, aged 63-93 years. Cerebrospinal fluid amyloid-ß levels were measured in a subset (n = 38) of participants. RSI measures of neurite density (ND) and isotropic free water (IF) were computed in fiber tracts and in hippocampal and entorhinal cortex gray matter, respectively. Analyses evaluated whether these measures predicted memory performance, correlated with amyloid-ß levels, and distinguished impaired individuals from controls. For comparison, analyses were repeated with standard diffusion tensor imaging (DTI) metrics of fractional anisotropy (FA) and mean diffusivity. RESULTS: Both RSI and DTI measures correlated with episodic memory and disease severity. RSI, but not DTI, measures correlated with amyloid-ß42 levels. ND and FA in the arcuate fasciculus and entorhinal cortex IF most strongly predicted recall performance. RSI measures of arcuate fasciculus ND and entorhinal cortex IF best discriminated memory impaired participants from healthy participants. CONCLUSIONS: RSI is highly sensitive to microstructural changes in the early stages of AD, and is associated with biochemical markers of AD pathology. Reduced ND in cortical association fibers and increased medial temporal lobe free-water diffusion predicted episodic memory, distinguished cognitively impaired from healthy individuals, and correlated with amyloid-ß. Although further research is needed to assess the sensitivity of RSI to preclinical AD and disease progression, these results suggest that RSI may be a promising tool to better understand neuroanatomical changes in AD and their association with neuropathology.
Subject(s)
Alzheimer Disease/complications , Alzheimer Disease/pathology , Brain/diagnostic imaging , Diffusion Tensor Imaging , Memory Disorders/etiology , Aged , Aged, 80 and over , Alzheimer Disease/cerebrospinal fluid , Alzheimer Disease/diagnostic imaging , Amyloid beta-Peptides/cerebrospinal fluid , Anisotropy , Female , Humans , Image Processing, Computer-Assisted , Male , Memory Disorders/cerebrospinal fluid , Memory Disorders/diagnostic imaging , Middle Aged , Neuropsychological Tests , Peptide Fragments/cerebrospinal fluid , Psychiatric Status Rating ScalesABSTRACT
Study Objectives: Obstructive sleep apnea (OSA) is a common sleep disorder. The, literature lacks studies examining sleep, cognition, and Alzheimer's Disease (AD) cerebrospinal fluid (CSF) biomarkers in OSA patients. Therefore, we first studied cognitive performances, polysomnographic sleep, and CSF ß-amyloid42, tau proteins, and lactate levels in patients affected by subjective cognitive impairment (SCI) divided in three groups: OSA patients (showing an Apnea-Hypopnea Index [AHI] ≥15/hr), controls (showing an AHI < 15/hr), and patients with OSA treated by continuous positive airway pressure (CPAP). Methods: We compared results among 25 OSA, 10 OSA-CPAP, and 15 controls who underwent a protocol counting neuropsychological testing in the morning, 48-hr polysomnography followed by CSF analysis. Results: OSA patients showed lower CSF Aß42 concentrations, higher CSF lactate levels, and higher t-tau/Aß42 ratio compared to controls and OSA-CPAP patients. OSA patients also showed reduced sleep quality and continuity and lower performances at memory, intelligence, and executive tests than controls and OSA-CPAP patients. We found significant relationships among higher CSF tau proteins levels, sleep impairment, and increased CSF lactate levels in the OSA group. Moreover, lower CSF Aß42 levels correlate with memory impairment and nocturnal oxygen saturation parameters in OSA patients. Conclusions: We hypothesize that OSA reducing sleep quality and producing intermittent hypoxia lowers CSF Aß42 levels, increases CSF lactate levels, and alters cognitive performances in SCI patients, thus inducing early AD clinical and neuropathological biomarkers changes. Notably, controls as well as OSA-CPAP SCI patients did not show clinical and biochemical AD markers. Therefore, OSA may induce early but possibly CPAP-modifiable AD biomarkers changes.
Subject(s)
Alzheimer Disease/cerebrospinal fluid , Alzheimer Disease/complications , Biomarkers/cerebrospinal fluid , Continuous Positive Airway Pressure , Early Medical Intervention , Sleep Apnea, Obstructive/complications , Sleep Apnea, Obstructive/therapy , Aged , Alzheimer Disease/prevention & control , Alzheimer Disease/therapy , Amyloid beta-Peptides/cerebrospinal fluid , Cognition , Cognitive Dysfunction/cerebrospinal fluid , Cognitive Dysfunction/complications , Cognitive Dysfunction/prevention & control , Cognitive Dysfunction/therapy , Early Diagnosis , Female , Humans , Intelligence , Lactic Acid/cerebrospinal fluid , Male , Memory , Memory Disorders/cerebrospinal fluid , Memory Disorders/complications , Memory Disorders/prevention & control , Memory Disorders/therapy , Neuropsychological Tests , Peptide Fragments/cerebrospinal fluid , Polysomnography , Sleep , Sleep Apnea, Obstructive/cerebrospinal fluid , Sleep Apnea, Obstructive/physiopathology , tau Proteins/cerebrospinal fluidABSTRACT
We studied whether continuous lower normal cerebrospinal fluid (CSF) amyloid ß1-42 (≥640pg/ml) levels were related with rate of clinical progression in a sample of 393 nondemented memory clinic patients. Lower normal levels were associated with faster clinical progression, and this depended on baseline cognitive status (subjective cognitive decline: hazard ratio [HR] = 0.57, p < 0.05; mild cognitive impairment: HR = 0.19, p < .01), indicating that normal CSF amyloid levels do not exclude incident Alzheimer disease. These findings suggest that research on preclinical markers for Alzheimer disease should take the continuum of CSF amyloid ß1-42 levels within the normal range into account. Ann Neurol 2017;81:749-753.
Subject(s)
Alzheimer Disease/cerebrospinal fluid , Amyloid beta-Peptides/cerebrospinal fluid , Cognitive Dysfunction/cerebrospinal fluid , Disease Progression , Memory Disorders/cerebrospinal fluid , Peptide Fragments/cerebrospinal fluid , Aged , Alzheimer Disease/physiopathology , Cognitive Dysfunction/physiopathology , Female , Follow-Up Studies , Humans , Male , Memory Disorders/physiopathology , Middle Aged , PrognosisABSTRACT
BACKGROUND: Type 2 diabetes is associated with an increased risk for Alzheimer's disease (AD). Regulation of normal insulin function may be important in reducing the prevalence of dementia due to AD, particularly in individuals who harbor genetic risk for or have a parental family history of AD. The relationship between insulin resistance (IR) and AD pathology remains poorly understood, particularly in midlife prior to the onset of clinical metabolic disease or cognitive decline. OBJECTIVE: We examined associations between IR as indexed by HOMA-IR, cerebrospinal fluid (CSF) biomarkers of AD pathology, and memory in middle-aged adults enriched for AD. We postulated that higher HOMA-IR and APOEÉ4 carriage would be associated with greater CSF AD pathology and poor memory performance. METHODS: Cognitively asymptomatic middle-aged adults (Nâ=â70, mean ageâ=â57.7 years) from the Wisconsin Alzheimer's Disease Research Center with a parental family history of dementia due to AD underwent lumbar puncture, blood draw, and neuropsychological testing. CSF AD biomarkers including soluble amyloid-ß protein precursor ß (sAßPPß), amyloid-ß42 (Aß42), and phosphorylated tau (P-tau181) were examined with respect to HOMA-IR and APOEÉ4 status. Delayed memory performance was examined with respect to HOMA-IR, CSF AD biomarkers, and APOEÉ4 status. RESULTS: Higher HOMA-IR was associated with higher sAßPPß and Aß42 . APOEÉ4 carriers had significantly higher levels of sAßPPα, sAßPPß, and P-tau181/Aß42 compared to noncarriers. The concurrent presence of higher HOMA-IR and CSF AD pathology predicted worse delayed memory performance. CONCLUSION: Overall, the findings suggest that IR and APOEÉ4 are contributing factors to the development of AD pathology in midlife, and provide support for targeting insulin function as a potentially modifiable risk factor for AD.
Subject(s)
Alzheimer Disease/cerebrospinal fluid , Biomarkers/cerebrospinal fluid , Insulin Resistance , Memory Disorders/metabolism , Aged , Amyloid beta-Peptides/cerebrospinal fluid , Amyloid beta-Protein Precursor/cerebrospinal fluid , Female , Humans , Male , Memory Disorders/cerebrospinal fluid , Middle Aged , Peptide Fragments/cerebrospinal fluid , Risk Factors , tau Proteins/cerebrospinal fluidABSTRACT
BACKGROUND: Limited information is available on short-term prognosis of Alzheimer's disease (AD) biomarkers in cerebrospinal fluid (CSF) in addition to routine diagnostic workup. OBJECTIVE: This study aims to investigate the added prognostic value of AD CSF biomarkers. METHODS: In a prospective cohort study, clinical experts predicted cognitive and functional symptoms in 114 memory clinic patients by assessing comprehensive routine diagnostic test information (patient history, and physical, neurological, psychiatric, neuropsychological, and MRI examinations), without and with CSF biomarkers. The reference standard was the 'observed clinically relevant decline' using baseline and 1- and 2-year follow-up information. RESULTS: Decline over a 2-year period was observed in 51% of all participants (3% in SMC, 48% in MCI, 90% in mild dementia). In the total sample, the accuracy of predicted decline did not differ significantly between routine assessment without (79% correctly predicted) and with (74% correctly predicted) CSF biomarkers. Subgroup analyses revealed 25 (83%) correct predictions in SMC, 30 (68%) in MCI, and 35 (88%) in dementia without the use of CSF; and 21 (70%), 27 (61%), and 36 (90%), respectively, with the use of CSF in addition to the routine assessment. CONCLUSION: AD CSF biomarkers did not increase accuracy of 2-year prognosis of cognitive and functional decline when added to routine diagnostic workup. This suggests that the standard diagnostic workup without CSF biomarkers allows fairly accurate predictions for the short-term course of symptoms. Routine AD biomarkers in CSF have limited prognostic value over 2 years in persons with a suspected cognitive disorder.
Subject(s)
Biomarkers/cerebrospinal fluid , Memory Disorders/cerebrospinal fluid , Aged , Aged, 80 and over , Alzheimer Disease/complications , Cohort Studies , Female , Humans , Male , Memory Disorders/etiology , Mental Status Schedule , Middle Aged , Prognosis , Reference ValuesABSTRACT
Analytical validation of a biomarker assay is essential before implementation in clinical practice can occur. In this study, we analytically validated the performance of assays detecting soluble amyloid-ß precursor protein (sAPP) α and ß in CSF in two laboratories according to previously standard operating procedures serving this goal. sAPPα and sAPPß ELISA assays from two vendors (IBL-international, Meso Scale Diagnostics) were validated. The performance parameters included precision, sensitivity, dilutional linearity, recovery, and parallelism. Inter-laboratory variation, biomarker comparison (sAPPα vs. sAPPß) and clinical performance was determined in three laboratories using 60 samples of patients with subjective memory complaints, Alzheimer's disease, or frontotemporal dementia. All performance parameters of the assays were similar between labs and within predefined acceptance criteria. The only exceptions were minor out-of-range results for recovery at low concentrations and, despite being within predefined acceptance criteria, non-comparability of the results for evaluation of the dilutional linearity and hook-effect. Based on the inter-laboratory correlation between Lab #1 and Lab #2, the IBL-international assays were more robust (sAPPα: r(2) = 0.92, sAPPß: r(2) = 0.94) than the Meso Scale Diagnostics (MSD) assay (sAPPα: r(2) = 0.70, sAPPß: r(2) = 0.80). Specificity of assays was confirmed using assay-specific peptide competitors. Clinical validation showed consistent results across the clinical groups in the different laboratories for all assays. The validated sAPP assays appear to be of sufficient technical quality and perform well. Moreover, the study shows that the newly developed standard operating procedures provide highly useful tools for the validation of new biomarker assays. A recommendation was made for renewed instructions to evaluate the dilutional linearity and hook-effect. We analytically validated the performance of assays detecting soluble amyloid-ß precursor protein (sAPP) α and ß in CSF according to SOPs in agreement with ISO15189 guidelines. The validated sAPP assays appear to be of sufficient technical quality and perform well. Moreover, this study proofs that the newly developed SOPs, with a minor modification, provide highly useful tools for the validation of new biomarker assays.
Subject(s)
Amyloid beta-Protein Precursor/cerebrospinal fluid , Enzyme-Linked Immunosorbent Assay , Laboratory Proficiency Testing , Neurodegenerative Diseases/cerebrospinal fluid , Peptide Fragments/cerebrospinal fluid , Reagent Kits, Diagnostic , Alzheimer Disease/cerebrospinal fluid , Alzheimer Disease/diagnosis , Biomarkers/cerebrospinal fluid , Frontotemporal Dementia/cerebrospinal fluid , Frontotemporal Dementia/diagnosis , Humans , Memory Disorders/cerebrospinal fluid , Memory Disorders/diagnosis , Neurodegenerative Diseases/diagnosis , Reproducibility of Results , Sensitivity and Specificity , SolubilitySubject(s)
Cognition Disorders/complications , Memory Disorders/etiology , Adult , Amyloid beta-Peptides/cerebrospinal fluid , Cognition Disorders/cerebrospinal fluid , Cognition Disorders/diagnostic imaging , Cognition Disorders/genetics , Humans , Magnetic Resonance Imaging , Male , Memory Disorders/cerebrospinal fluid , Memory Disorders/diagnostic imaging , Memory Disorders/genetics , Mental Status Schedule , Peptide Fragments/cerebrospinal fluid , Presenilin-1/genetics , tau Proteins/cerebrospinal fluidABSTRACT
BACKGROUND: There is a need to find very early markers for pre-clinical Alzheimer's disease as interventions early in the disease process are thought to be most effective. OBJECTIVE: The present study aimed to address the potential relation between cerebrospinal fluid (CSF) biomarkers and reduced cognitive function in a relatively young cohort of memory clinic patients with subjective cognitive decline. METHODS: 122 patients (mean age 63 years) with subjective cognitive decline were recruited from two university memory clinics and followed for two years. RESULTS: The main finding was that the subgroup with objective memory decline during the study period had significantly higher T-tau at baseline than the group with improved memory. Baseline CSF variables showed a trend toward more pathological values in the patients with memory decline compared to those who improved or remained stable. The baseline memory score of those who declined was significantly better than the baseline score of those who improved over two years. The general trend for the whole group was improved memory and executive test scores. There were no differences in cognitive scores based on CSF quartiles at baseline, nor were there differences in cognitive outcome for patients with early amnestic mild cognitive impairment versus average cognitive function at baseline. CONCLUSIONS: The main finding that T-tau rather than amyloid-ß was associated with memory decline do not support the prevailing opinion about the chain of events assumed to take place in Alzheimer's disease. In addition, memory decline was not associated with poor baseline memory score. Thus, a memory cut-off indicating low baseline memory would not would have identified the declining group.